Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation-Reference-Cited by-同舟云学术

Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation

Published:2018-07 Issue:1 Volume:94 Page:114-125
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Liu Pan,Wysocki Jan,Souma Tomokazu,Ye Minghao,Ramirez Veronica,Zhou Bisheng,Wilsbacher Lisa D.,Quaggin Susan E.,Batlle Daniel,Jin Jing

Publisher

Elsevier BV

Subject

Nephrology

Reference62 articles.

1. Novel RAAS agonists and antagonists: clinical applications and controversies;Romero;Nat Rev Endocrinol,2015

2. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease;Raij;Am J Hypertens,2005

3. ACE2: angiotensin II/angiotensin-(1–7) balance in cardiac and renal injury;Varagic;Curr Hypertens Rep,2014

4. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy;Batlle;Kidney Int,2012

5. New aspects of the renin–angiotensin system: angiotensin-converting enzyme 2 – a potential target for treatment of hypertension and diabetic nephropathy;Batlle;Curr Opin Nephrol Hypertens,2008

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation;Molecular Therapy - Methods & Clinical Development;2024-09

2. Activation of limbal epithelial proliferation is partly controlled by the ACE2-LCN2 pathway;iScience;2024-08

3. Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection;Frontiers in Immunology;2024-04-05

4. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity;Scientific Reports;2024-03-08

5. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks;Antibody Therapeutics;2023-12-12